Another study indicates that NRF2 interacts with p53 mutants in breast cancer cells [37]; and APR-246, a first-in-class mutant p53 reactivator, disrupts the interaction between mutant P53 and NRF2 [37]. This evidence concerns the gene TP53 and breast cancer.